Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Korro Bio is a clinical-stage biotechnology company developing RNA editing therapeutics using its proprietary ADAR (adenosine deaminase acting on RNA) platform technology. The company focuses on editing RNA rather than DNA, targeting genetic diseases affecting the liver, central nervous system, and other tissues. With no commercial revenue and a $100M market cap, Korro is a pre-revenue biotech dependent on clinical trial progression and partnership deals to fund operations through its substantial cash runway (6.71x current ratio).
Korro operates a platform business model where it develops proprietary ADAR-mediated RNA editing technology to create therapeutic candidates for genetic diseases. The company monetizes through: (1) internal pipeline development leading to eventual product sales post-FDA approval, (2) licensing deals with large pharma partners providing upfront payments, milestone payments tied to clinical/regulatory achievements, and royalties on commercialized products, and (3) potential acquisition by larger biopharma companies seeking RNA editing capabilities. The ADAR platform's competitive advantage lies in its ability to make precise, reversible RNA edits without permanently altering DNA, potentially offering better safety profiles than CRISPR-based gene editing. Pricing power will depend on demonstrating clinical efficacy in high-unmet-need indications where patients/payers accept $200K-$1M+ annual treatment costs typical of rare disease therapies.
Clinical trial data readouts - particularly Phase 1/2 safety and preliminary efficacy results for lead programs in liver and CNS diseases
Partnership announcements with large pharmaceutical companies (upfront payments, validation of platform technology)
FDA regulatory milestones - IND clearances for new programs, Fast Track or Orphan Drug designations
Financing events - equity raises, debt facilities, or PIPE transactions that extend cash runway or signal institutional confidence
Competitive developments in RNA editing space (competitors include Wave Life Sciences, ProQR Therapeutics, and academic ADAR research)
Scientific publications or conference presentations demonstrating platform advantages over DNA editing approaches
RNA editing technology validation risk - ADAR-mediated editing is earlier-stage than CRISPR/Cas9 DNA editing, with limited clinical proof-of-concept data industry-wide; platform may face unforeseen safety issues (immunogenicity, off-target editing) or efficacy limitations
Regulatory pathway uncertainty - FDA has limited precedent for RNA editing therapies, potentially leading to unpredictable clinical trial requirements, longer approval timelines, or restrictive labeling compared to traditional small molecules
Competitive technology displacement - CRISPR-based in vivo gene editing, antisense oligonucleotides (ASOs), and siRNA platforms are more mature with established clinical success; if these modalities prove superior for Korro's target indications, the ADAR platform becomes obsolete
Well-funded competitors in RNA/gene editing space including Wave Life Sciences (ADAR editing), Beam Therapeutics (base editing), Intellia Therapeutics (CRISPR), and large pharma internal programs at Eli Lilly, Regeneron, and Vertex - many with deeper pipelines and partnership resources
Patent landscape complexity - ADAR editing involves foundational IP from academic institutions and multiple biotech companies; potential for patent litigation, licensing requirements, or freedom-to-operate challenges that increase costs or delay programs
Target indication competition - even if ADAR technology works, specific disease programs face competition from alternative therapeutic modalities (enzyme replacement, small molecules, monoclonal antibodies) already in late-stage development
Cash runway risk - with -$100M annual operating cash flow and $100M market cap, company likely needs additional financing within 12-18 months; equity raises at current depressed valuation (down 60.8% over 1 year) would be highly dilutive to existing shareholders
Going concern risk if unable to secure financing - biotech sector funding environment deteriorated significantly in 2022-2024; if capital markets remain closed and partnership deals don't materialize, company may face strategic alternatives including asset sales, merger at unfavorable terms, or bankruptcy
Debt covenant risk - 0.45x debt/equity ratio indicates some leverage; if debt facilities have milestone-based covenants or cash balance requirements, failure to meet these could trigger acceleration or restrictive amendments
low - Biotech drug development timelines (8-12 years from discovery to approval) are largely insulated from short-term economic cycles. Patient demand for life-saving genetic disease treatments remains inelastic regardless of GDP growth. However, the company's ability to raise capital is highly sensitive to risk appetite in public/private biotech financing markets, which correlates with broader equity market conditions and economic confidence.
High sensitivity through valuation multiples and financing costs. Rising interest rates compress biotech valuations significantly because: (1) pre-revenue biotechs are valued on discounted cash flows from products 5-10+ years away, making them duration-sensitive like long-dated bonds, (2) higher risk-free rates reduce relative attractiveness of high-risk/high-return biotech investments, and (3) increased cost of capital for future equity raises or debt financing. The 10-year Treasury yield directly impacts discount rates used in DCF models for pipeline assets. Additionally, venture capital and crossover fund allocation to biotech contracts when rates rise, reducing available financing.
Minimal direct credit exposure - company does not extend credit to customers (no revenue) or rely on credit-sensitive end markets. However, indirectly exposed to credit conditions through: (1) ability to access debt financing or venture debt facilities to extend runway, (2) pharmaceutical partners' willingness to commit capital to licensing deals during credit stress, and (3) IPO/follow-on equity markets which freeze during credit crises, forcing dilutive financings or down rounds.
growth/speculative - Attracts high-risk-tolerance investors seeking asymmetric returns from binary clinical trial outcomes. Typical shareholders include specialized biotech hedge funds, venture capital crossover funds, and retail investors with sector expertise. Not suitable for value investors (no earnings, high cash burn) or income investors (no dividends). The 84.6% three-month return followed by -60.8% one-year return exemplifies the momentum-driven, event-based trading pattern. Institutional ownership likely concentrated among funds with dedicated healthcare analyst teams capable of evaluating complex scientific and regulatory risks.
high - Pre-revenue, clinical-stage biotechs exhibit extreme volatility driven by binary clinical trial outcomes, financing events, and sector rotation. Stock likely has beta >2.0 relative to broader market, with single-day moves of 20-50%+ common around data readouts. The 84.6% three-month gain against -60.8% one-year loss demonstrates characteristic whipsaw price action. Implied volatility on options (if available) typically 80-150%+ for clinical-stage names. Low float and market cap amplify volatility as small order flows create outsized price impact.